Genkyotex : Adjustment of the target price after the regrouping of shares
>Regrouping of shares by 10 - We are updating our model following the announcement a few days ago of the completion of the regrouping of shares by 10. This has no impact on our valuation, so shareholders with 10 shares end up with a single share whose value increases accordingly. We have adjusted our target price from € 1 per share to € 10.GKT831: Imminent publication of final PII PBC results - On 11 March, the company announced the end of the 24-wee...Genkyotex is engaged in the identification and development of selective NADPH Oxidase ("NOX") inhibitors to treat specific diseases, the therapeutic benefit of which has not yet been demonstrated. Co. is developing a new therapeutic approach based on the selective inhibition of NOX enzymes which are identified as potentially key factors in the development of certain complex illnesses that are difficult to treat, such as hepatic, pulmonary and renal fibrosis, certain forms of cancer, neurodegenerative diseases or even hearing problems. The capacity of NOXs to simultaneously regulate protein networks makes them a therapeutic target.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.